Small molecule stimulators of the proteasome core particle
Compounds stimulate the 20S CP of the UPS to improve protein degradation, addressing inefficiencies in the UPS and enhancing protein clearance for therapeutic applications.
Patent Information
- Application Number
- JP2022509051
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-16
- Filing Date
- 2020-08-14
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2040-08-14
AI Technical Summary
The ubiquitin-proteasome system (UPS) is inefficient in degrading intrinsically impaired or oxidatively damaged proteins, leading to their accumulation and interference with cellular processes, which is a hallmark of various diseases.
Development of compounds that stimulate the 20S core particle (CP) of the UPS to enhance protein degradation by increasing substrate entry and hydrolytic activity, using small molecules like miconazole and its derivatives.
The compounds significantly increase the degradation of proteins, such as alpha-synuclein, by 200-300% compared to controls, demonstrating enhanced protein clearance and potential therapeutic benefits.
Smart Images

Figure 0007583027000036 
Figure 0007583027000037 
Figure 0007583027000038
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This patent application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62 / 887,732, filed August 16, 2019, the entire contents of which are incorporated herein by reference.
[0002] Technical Field The present disclosure relates to a series of compounds and methods of use for treating diseases caused by dysregulation of the ubiquitin-proteasome system (UPS), which are effective stimulators of the 20S core particle (CP) of the UPS. The compositions and methods of use are within the scope of the present disclosure. [Background technology]
[0003] background The major protein degradation pathway within cells is the ubiquitin-proteasome system (UPS). 1 This system involves a protein network that polyubiquitinates and degrades protein substrates. The degradation process is carried out by the 26S proteasome, which is composed of the 19S regulatory particle (19S RP) and the 20S core particle (20S CP). The 20S CP is responsible for the hydrolytic activity, breaking down proteins into shorter peptides, and is controlled by the 19S RP, which recognizes ubiquitinated substrates, removes ubiquitin, and coordinates the movement of the substrate with the catalytic core particle for degradation. 2 However, the activity of the 20S CP does not depend on the presence of regulatory particles: in the ubiquitin-independent proteasome system (UIPS), intrinsically damaged or oxidatively damaged proteins that lack significant secondary structure can enter the uncapped 20S CP for degradation. 3、4 However, this degradation process is slower than that carried out by the 26S proteasome due to the slow rate of substrate entry.
[0004] Many disease states are characterized by the accumulation of proteins, generally damaged or damaged proteins, which accumulation leads to aggregation. 5~7 Aggregated forms of these proteins can interfere with normal cellular processes such as mitochondrial function and protein degradation pathways. 8~10 It has been hypothesized that the 20S CP could be chemically stimulated to enhance substrate entry or improve its hydrolytic activity in order to more rapidly degrade these potentially harmful proteins. 11、12 Chemical intervention and control of the UPS offers a potential solution to the unmet need for medical treatment of a variety of human diseases. Summary of the Invention [Means for solving the problem]
[0005] Quick Overview In some exemplary embodiments, the present disclosure provides a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, wherein, independently, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; C represents three identical or different substituents, each independently being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above three, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0006] In some exemplary embodiments, the present disclosure provides a compound of formula (II): [ka] and for a 20S CP stimulant compound having the formula: A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0007] In some exemplary embodiments, the disclosure relates to a 20S CP stimulant compound having formula (II) as disclosed herein, wherein: A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; B represents five of the same or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl.
[0008] In some exemplary embodiments, the disclosure relates to a 20S CP stimulant compound having formula (II) as disclosed herein, said compound comprising: [ka] It is.
[0009] In some exemplary embodiments, the present disclosure provides a compound of formula (III): [ka] and for a 20S CP stimulant compound having the formula: X - is the counter ion, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; D represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0010] In some exemplary embodiments, the present disclosure provides a compound of formula (IV): [ka] and for a 20S CP stimulant compound having the formula: X - is the counter ion, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0011] In some exemplary embodiments, the disclosure relates to a 20S CP stimulator compound having formula (I), (II), (III), or (IV) as disclosed herein, wherein two of the five substituents of A are halo.
[0012] In some exemplary embodiments, the disclosure relates to a 20S CP stimulator compound having formula (I), (II), (III), or (IV) as disclosed herein, wherein two of the five substituents of B are halo.
[0013] In some exemplary embodiments, the present disclosure relates to a 20S CP stimulant compound having formula (I), (II), (III), or (IV) as disclosed herein, wherein the counterion is a halide.
[0014] In some exemplary embodiments, the disclosure provides a 20S CP stimulant compound disclosed herein, comprising: [ka] The present invention relates to a compound wherein
[0015] In certain other exemplary embodiments, the present disclosure relates to pharmaceutical compositions comprising a 20S CP stimulant compound having formula (I), (II), (III), or (IV) disclosed herein.
[0016] In some other exemplary embodiments, the disclosure relates to a pharmaceutical composition comprising a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein, wherein said compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS), said composition for use in treating a disease caused by dysregulation of the UPS.
[0017] In some other exemplary embodiments, the disclosure relates to the use of a pharmaceutical composition in the preparation of a medicament for treating a disease caused by dysregulation of the UPS, wherein said pharmaceutical composition comprises a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein.
[0018] In some other exemplary embodiments, the disclosure relates to the use of a pharmaceutical composition in the preparation of a medicament for treating a disease caused by dysregulation of the UPS, wherein said pharmaceutical composition comprises a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein, wherein said compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS).
[0019] In some other exemplary embodiments, the present disclosure relates to a method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having the general formula (I), (II), (III), or (IV) or a pharma- ceutically acceptable salt thereof. [Brief description of the drawings]
[0020] [Figure 1] FIG. 1 shows the schematic structure of miconazole, a previously unreported small molecule irritant of the 20S CP.
[0021] [Figure 2A]Figure 2A shows the results of testing miconazole in a standard FRET assay, plotting relative fluorescence units versus time (min). Figure 2B demonstrates that miconazole has a stimulatory effect with standard 20S CP (sCP) and the immune proteasome (iCP), but not with the 26S proteasome (26S). Figure 2C shows that dose-response analysis of miconazole with various concentrations of sCP reveals that miconazole has an EC50 of 20 μM. [Figure 2B] Figure 2A shows the results of testing miconazole in a standard FRET assay, plotting relative fluorescence units versus time (min). Figure 2B demonstrates that miconazole has a stimulatory effect with standard 20S CP (sCP) and the immune proteasome (iCP), but not with the 26S proteasome (26S). Figure 2C shows that dose-response analysis of miconazole with various concentrations of sCP reveals that miconazole has an EC50 of 20 μM. [Figure 2C] Figure 2A shows the results of testing miconazole in a standard FRET assay, plotting relative fluorescence units versus time (min). Figure 2B demonstrates that miconazole has a stimulatory effect with standard 20S CP (sCP) and the immune proteasome (iCP), but not with the 26S proteasome (26S). Figure 2C shows that dose-response analysis of miconazole with various concentrations of sCP reveals that miconazole has an EC50 of 20 μM.
[0022] [Diagram 3] FIG. 3 shows an analysis of 20S CP-mediated degradation of various proteins in the absence and presence of miconazole.
[0023] [Figure 4] Figure 4 shows a GFP-alpha-synuclein fusion assay performed in duplicate. Molecules were administered at 25 μM for 16 hours.
[0024] [Diagram 5]Figure 5 shows quantification of the gel bands from Figure 4. Both MDX1 and MDX2 resulted in increased alpha-synuclein degradation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] Detailed Description For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to the embodiments illustrated in the drawings, and specific language will be used to describe the same, it being understood nevertheless that no limitation of the scope of the disclosure is intended thereby.
[0026] Those skilled in the art will appreciate that numerous modifications can be made to the specific implementations described above. The implementations should not be limited to the specific limitations described. Other implementations may be possible.
[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. Although any methods, materials, compositions, reagents, cells similar or equivalent to those described herein can be used in the practice or testing of the subject matter of this disclosure, preferred methods and materials are described. All publications and references cited herein, including but not limited to patents and patent applications, are incorporated herein by reference in their entirety, as if each individual publication or reference was specifically and individually indicated to be incorporated herein by reference as if fully set forth. Any patent application to which this application claims priority is also incorporated herein by reference in its entirety in the manner described above for publications and references.
[0028] Values expressed in range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also all individual numerical values or subranges subsumed within the range, as if each numerical value and subrange were explicitly recited. In this disclosure, the term "about" can allow the degree of variation of a value or range to be, for example, within 10%, within 5%, or within 1% of the stated value or the limit of the stated range. In this disclosure, the term "substantially" can allow the degree of variation of a value or range to be, for example, within 60%, within 80%, within 90%, within 95%, or within 99%, or more, of the stated value or the limit of the stated range.
[0029] In this document, the terms "a", "an", or "the" are used to include one or more than one, unless the context clearly indicates otherwise. The term "or" is used to refer to a non-exclusive "or", unless otherwise indicated. Furthermore, it will be understood that the language or terminology used herein, unless otherwise defined, is merely for descriptive purposes and not limiting. Any use of section headings is intended to aid in the reading of the document and is not to be construed as limiting. Furthermore, the information relevant to a section heading may occur within or outside that particular section. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated herein by reference in their entirety as if individually incorporated by reference. In the event of any conflicting usage between this document and those documents so incorporated by reference, the usage in the incorporated references should be considered as supplementing the usage in this document; in the event of an irreconcilable conflict, the usage in this document will control.
[0030] As used herein, the term "organic group" refers to any carbon-containing functional group, including, but not limited to, oxygen-containing groups such as alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups, including carboxylic acids, carboxylates, and carboxylic esters; sulfur-containing groups, such as alkyl and aryl sulfide groups; and other heteroatom-containing groups.
[0031] The term "substituted" as used herein refers to an organic group as defined herein or a molecule in which one or more hydrogen atoms contained therein are replaced by one or more non-hydrogen atoms. The term "functional group" or "substituent" as used herein refers to a group that can be present or substituted on a molecule or on an organic group. Examples of substituents or functional groups include, but are not limited to, halogens (e.g., F, Cl, Br, and I); oxygen atoms in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups, including carboxylic acids, carboxylates, and carboxylic acid esters; sulfur atoms in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; nitrogen atoms in groups such as amines, hydroxylamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups.
[0032] As used herein, the term "alkyl" refers to substituted or unsubstituted straight-chain and branched alkyl and cycloalkyl groups having from 1 to 40 carbon atoms (C 1 ~C 40 ), 1 to about 20 carbon atoms (C 1 ~C 20 ), 1 to 12 carbons (C 1 ~C 12 ), 1 to 8 carbon atoms (C 1 ~C 8 ), or in some embodiments, 1 to 6 carbon atoms (C 1~C 6 ) refers to groups having an alkyl group. Examples of straight chain alkyl groups include those having 1 to 8 carbon atoms, such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, isobutyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. As used herein, the term "alkyl" includes n-alkyl, isoalkyl, and anteisoalkyl groups, as well as other branched forms of alkyl. Representative substituted alkyl groups can be substituted one or more times with any of the groups enumerated herein, such as amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
[0033] As used herein, the term “alkenyl” refers to substituted or unsubstituted straight-chain and branched divalent alkenyl and cycloalkenyl groups having from 2 to 20 carbon atoms (C 2 ~C 20 ), 2 to 12 carbons (C 2 ~C 12 ), 2 to 8 carbon atoms (C 2 ~C 8 ), or in some embodiments, 2 to 4 carbon atoms (C 2 ~C 4 ), and groups having at least one carbon-carbon double bond. Examples of linear alkenyl groups include, for example, -CH=CH-, -CH=CHCH 2 -, and the like. Examples of branched alkenyl groups include, but are not limited to, -CH=C(CH 3 )-and the like.
[0034] As used herein, the term “alkylene” refers to substituted or unsubstituted straight-chain and branched divalent alkylene and cycloalkylene groups having from 1 to 40 carbon atoms (C 1 ~C 40 ), 1 to about 20 carbon atoms (C 1~C 20 ), 1 to 12 carbons (C 1 ~C 12 ), 1 to 8 carbon atoms (C 1 ~C 8 ), or in some embodiments, 1 to 4 carbon atoms (C 1 ~C 4 ), 1 to 5 carbon atoms (C 1 ~C 5 ), 2 to 5 carbon atoms (C 2 ~C 5 ), or 3 to 4 carbon atoms (C 3 ~C 4 ). Examples of straight chain alkylene groups include those having 1 to 8 carbon atoms, such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), n-propylene (-CH 2 CH 2 CH 2 -), n-butylene (-CH 2 (CH 2 ) 2 CH 2 -), and the like. Examples of branched alkylene groups include, but are not limited to, isopropylidene (CH 2 CH(CH 3 )) and the like. Examples of cycloalkylene groups include, but are not limited to, cyclopropylidene, cyclobutylidene, cyclopentylidene, and the like.
[0035] The term "hydroxyalkyl," as used herein, refers to an alkyl group, as defined herein, substituted with at least one hydroxyl (-OH) group.
[0036] The term "cycloalkyl" as used herein refers to substituted or unsubstituted cyclic alkyl groups, such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, cycloalkyl groups can have from 3 to about 8-12 ring members, while in other embodiments the number of ring carbon atoms ranges from 3 to 4, 5, 6, or 7. In some embodiments, cycloalkyl groups can have from 3 to 6 carbon atoms (C 3 ~C 6 Cycloalkyl groups can also include polycyclic cycloalkyl groups, such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, as well as fused rings, such as, but not limited to, decalinyl, and the like.
[0037] The term "acyl" as used herein refers to a group containing a carbonyl moiety, which is bonded through the carbonyl carbon atom. The carbonyl carbon atom is also bonded to another carbon atom, which may be part of a substituted or unsubstituted alkyl, aryl, aralkylcycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group, or the like. In the special case where the carbonyl carbon atom is bonded to a hydrogen, the group is a "formyl" group, an acyl group, as that term is defined herein. An acyl group can contain 0 to about 12-40, 6-10, 1-5, or 2-5 additional carbon atoms bonded to the carbonyl group. An acryloyl group is an example of an acyl group. An acyl group can also contain heteroatoms within the meaning of this specification. A nicotinoyl group (pyridyl-3-carbonyl) is an example of an acyl group within the meaning of this specification. Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups, and the like. When the group containing the carbon atom bonded to the carbonyl carbon atom contains a halogen, the group is referred to as a "haloacyl" group. An example is the trifluoroacetyl group.
[0038] The term "heterocyclylcarbonyl" is an example of an acyl group attached to a substituted or unsubstituted heterocyclyl group, as the term "heterocyclyl" is defined herein. An example of a heterocyclylcarbonyl group is a prolyl group, which can be a D- or L-prolyl group.
[0039] The term "aryl" as used herein refers to a substituted or unsubstituted cyclic aromatic hydrocarbon that does not contain heteroatoms in the ring. Thus, aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups. In some embodiments, aryl groups are from about 6 to about 14 carbons (C 6 ~C 14 ) or 6 to 10 carbon atoms (C 6 ~C 10 ) in the ring portion of the group. Aryl groups can be unsubstituted or substituted as defined herein. Representative substituted aryl groups can be mono- or multiply substituted, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl, or 2-8 substituted naphthyl groups, which can be substituted with carbon or non-carbon groups such as those enumerated herein.
[0040] The terms "aralkyl" and "arylalkyl" as used herein refer to an alkyl group, as defined herein, in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to an aryl group, as defined herein. Representative aralkyl groups include benzyl and phenylethyl groups, and fused (cycloalkylaryl)alkyl groups, such as 4-ethyl-indanyl. An aralkenyl group is an alkenyl group, as defined herein, in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to an aryl group, as defined herein.
[0041] The term "heterocyclyl" as used herein refers to substituted or unsubstituted aromatic and non-aromatic ring compounds containing three or more ring members, one or more of which is a heteroatom, such as, but not limited to, N, O, and S. A heterocyclyl can thus be a cycloheteroalkyl or heteroaryl, or, if polycyclic, any combination thereof. In some embodiments, heterocyclyl groups contain from 3 to about 20 ring members, whereas other such groups have from 3 to about 15 ring members. In some embodiments, heterocyclyl groups contain from 3 to 8 carbon atoms (C 3 ~C 8 ), 3 to 6 carbon atoms (C 3 ~C 6 ), or 6 to 8 carbon atoms (C 6 ~C 8 ) heterocyclyl groups. 2 A heterocyclyl group represented as -heterocyclyl can be a 5-ring ring having 2 carbon atoms and 3 heteroatoms, a 6-ring ring having 2 carbon atoms and 4 heteroatoms, etc. 4 -Heterocyclyl can be a 5-ring ring with one heteroatom, a 6-ring ring with two heteroatoms, etc. The number of carbon atoms plus the number of heteroatoms equals the total number of ring atoms. Heterocyclyl rings can also contain one or more double bonds. Heteroaryl rings are embodiments of heterocyclyl groups. The term "heterocyclyl group" includes fused ring species, including those containing fused aromatic and non-aromatic groups. Representative heterocyclyl groups include, but are not limited to, pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, chromanyl, indolinyl, isoindolinyl, furanyl, pyrrolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, triazinyl, thiophenyl, tetrahydrofuranyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, triazyolyl, tetrazolyl, benzoxazolinyl, benzthiazolinyl, and benzimidazolinyl groups.
[0042] The term "heteroarylalkyl," as used herein, refers to an alkyl group, as defined herein, in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a heteroaryl group, as defined herein.
[0043] As used herein, the term "amine" refers to primary, secondary, and tertiary amines. Amines include, but are not limited to, R-NH 2 , for example alkylamines, arylamines, alkylarylamines; R 2 NH, where each R is independently selected, e.g., dialkylamines, diarylamines, aralkylamines, heterocyclylamines, and the like; and R 3 N, where each R is independently selected, includes, for example, trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like. The term "amine" as used herein also includes ammonium ions.
[0044] As used herein, the term "amino group" refers to an -NH 2 , -NHR, -NR 2 , -NR 3 + where each R is independently selected and cannot be protonated -NR 3 + Each is in its protonated form, except for . Thus, any compound substituted with an amino group can be viewed as an amine. An "amino group" within the meaning of this specification can be a primary, secondary, tertiary, or quaternary amino group. An "alkylamino" group includes monoalkylamino, dialkylamino, and trialkylamino groups.
[0045] The terms "halo," "halogen," or "halide" group as used herein, by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
[0046] As used herein, the term "haloalkyl" group includes monohaloalkyl groups, polyhaloalkyl groups where all halo atoms can be the same or different, and perhaloalkyl groups in which all hydrogen atoms are replaced by halogen atoms such as fluoro. Examples of haloalkyl include trifluoromethyl, 1,1-dichloroethyl, perfluorobutyl, -CF(CH 3 ) 2 , and the like.
[0047] As used herein, the terms "salt" and "pharmaceutically acceptable salt" refer to derivatives of the disclosed compounds, where the parent compound is modified by making its acid or base salt. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups, such as amines; and alkali or organic salts of acidic groups, such as carboxylic acids. Pharmaceutically acceptable salts include conventional non-toxic salts, or quaternary ammonium salts of the parent compound, formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from salts prepared from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids; and from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfamic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanedisulfonic, oxalic, and isethionic acid, and the like.
[0048] Pharmaceutically acceptable salts can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods.In some cases, such salts can be prepared by reacting these compounds in free acid or base form with stoichiometric amounts of appropriate base or acid in water or in an organic solvent or in a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.A list of suitable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, the disclosure of which is incorporated herein by reference.
[0049] The term "solvate" means a compound or a salt thereof that further contains a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. When the solvent is water, the solvate is a hydrate.
[0050] The term "prodrug" refers to a derivative of a compound that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vitro or in vivo) to provide an active compound, particularly a compound of the present invention. Examples of prodrugs include derivatives and metabolites of the compounds of the present invention that contain biohydrolyzable moieties, such as, but not limited to, biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogs. Particular prodrugs of compounds with a carboxyl functional group are lower alkyl esters of the carboxylic acid. Carboxylic acid esters are conveniently formed by esterification of any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers GmbH).
[0051] Various embodiments of the present invention also contemplate pharmaceutical compositions comprising one or more compounds of various embodiments of the present invention and one or more pharma- ceutically acceptable carriers, diluents, excipients, or combinations thereof. A "pharmaceutical composition" refers to a chemical or biological composition suitable for administration to a subject (e.g., a mammal). Such compositions may be specifically formulated for administration via one or more of several routes, including, but not limited to, buccal, dermal, epidermal, epidural, infusion, inhalation, intraarterial, intracardiac, intraventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, oral, parenteral, pulmonary, rectal via enema or suppository, subcutaneous, subdermal, sublingual, transdermal, and transmucosal. Furthermore, administration may be by capsule, drop, foam, gel, gum, injection, liquid, patch, pill, porous pouch, powder, tablet, or other suitable means of administration.
[0052] A "pharmaceutical excipient" or "pharmaceutical acceptable excipient" includes a carrier, sometimes a liquid, in which an active therapeutic agent is formulated. An excipient generally does not provide any pharmacological activity to the formulation, but can provide chemical and / or biological stability and release characteristics. Examples of suitable formulations can be found, for example, in Remington, The Science And Practice of Pharmacy, 20th Edition, (Gennaro, AR, Chief Editor), Philadelphia College of Pharmacy and Science, 2000, which is incorporated herein by reference in its entirety.
[0053] As used herein, "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual, or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, its use in the pharmaceutical compositions of the present invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[0054] The pharmaceutical composition may be sterile and stable under the conditions of manufacture and storage. The composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable for high drug concentration. The carrier may be a solvent or dispersion medium, for example, containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and appropriate mixtures thereof. Proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersion, and by the use of surfactants.
[0055] In many cases, it will be preferable to include an isotonic agent, such as sugar, polyalcohol, such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable composition can be achieved by including an agent that delays absorption, such as monostearate salts and gelatin, in the composition. In addition, the compounds described herein can be formulated as time-release preparations, such as compositions that include slow-release polymers. The active compound can be prepared with a carrier that will protect the compound from rapid release, such as a controlled release preparation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid, and polylactic acid, polyglycolic acid copolymers (PLG). Many methods for preparing such preparations are known to those skilled in the art.
[0056] Oral dosage forms are also contemplated herein. The pharmaceutical composition of the present invention may be orally administered as a capsule (hard or soft), a tablet (film-coated, enteric-coated, or uncoated), a powder or granule (coated or uncoated), or a liquid (solution or suspension). The formulation may be conveniently prepared by any of the methods well known in the art. The pharmaceutical composition of the present invention may contain one or more suitable formulation aids or excipients, including fillers, binders, disintegrants, lubricants, diluents, flow agents, buffers, wetting agents, preservatives, colorants, sweeteners, flavorings, and pharma- ceutically compatible carriers.
[0057] For each of the enumerated embodiments, the compound can be administered by various dosage forms known in the art.Any biologically acceptable dosage form known to those skilled in the art and its combination are contemplated.Examples of such dosage forms include, but are not limited to, chewable tablets, quick-dissolving tablets, effervescent tablets, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-layer tablets, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, beads, powders, gums, granules, particles, microparticles, dispersible granules, cachets, douches, suppositories, creams, topicals, inhalants, aerosol inhalants, patches, particle inhalants, implants, depot implants, ingestible substances, injectable substances (including subcutaneous, intramuscular, intravenous, and intradermal), infusions, and combinations thereof.
[0058] Other compounds which may be included in the mixture include, for example, medically inert ingredients (e.g., solid and liquid diluents), such as lactose, dextrose, saccharose, cellulose, starch, or calcium phosphate for tablets or capsules, olive oil or ethyl oleate for soft capsules, and water or vegetable oil for suspensions or emulsions; lubricants, such as silica, talc, stearic acid, magnesium or calcium stearate, and / or polyethylene glycol; gelling agents, such as colloidal clays; thickening agents, such as gum tragacanth or sodium alginate, binding agents, such as starch, gum arabic, gelatin, methylcellulose, carboxymethylcellulose, or polyvinylpyrrolidone; disintegrating agents, such as starch, alginic acid, alginates, or sodium starch glycolate; effervescent mixtures; dyes; sweeteners; wetting agents, such as lecithin, polysorbates, or lauryl sulfate; and other therapeutically acceptable auxiliary ingredients, such as humectants, preservatives, buffers, and antioxidants, which are known additives for such formulations.
[0059] The liquid dispersions for oral administration can be syrups, emulsions, solutions or suspensions.Syrups can contain as carriers, for example, saccharose, or saccharose with glycerol and / or mannitol and / or sorbitol.Suspensions and emulsions can contain carriers, for example, natural gums, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
[0060] The amount of active compound in the therapeutic composition according to various embodiments of the present invention may vary depending on factors such as disease state, age, sex, weight, patient history, risk factors, predisposition to disease, route of administration, existing treatment regime (e.g., possible interactions with other medicines), and individual body weight.Dosage regimen may be adjusted to provide optimal therapeutic response.For example, a single bolus may be administered, or several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
[0061] As used herein, "dosage unit form" refers to a physically discrete unit suitable as a single dosage for a mammalian subject to be treated; each unit contains a predetermined amount of active compound calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier. The specifications for the dosage unit forms of the present invention are determined by and directly depend on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, as well as the limitations inherent in the art of compounding such active compounds for the treatment of susceptibility in an individual. In therapeutic applications for treating conditions in a mammal (e.g., human) for which the compound of the present invention or a suitable pharmaceutical composition thereof is effective, the compound of the present invention can be administered in an effective amount. The dosage suitable for the present invention may be a composition, pharmaceutical composition, or any other composition described herein.
[0062] For each of the enumerated embodiments, dosages are typically administered once, twice, or three times daily, although more frequent dosing intervals are possible. Dosages may be administered daily, every 2nd, 3rd, 4th, 5th, 6th, and / or every 7th day (once per week). In one embodiment, dosages may be administered daily, preferably for 7-10 days, up to and including the 30th day. In another embodiment, dosages may be administered twice daily for 10 days. If a patient requires treatment for a chronic disease or condition, dosages may be administered as long as signs and / or symptoms persist. Patients may require "maintenance treatment," where the patient receives dosages daily for months, years, or the remainder of their life. Additionally, the compositions of the present invention may be for providing prevention of recurrent symptoms. For example, dosages may be administered once or twice daily to prevent the onset of symptoms in at-risk patients, particularly asymptomatic patients.
[0063] The compositions described herein may be administered by any of the following routes: buccal, epicutaneous, epidural, infusion, inhalation, intra-arterial, intracardiac, intraventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, buccal, parenteral, pulmonary, rectal via enema or suppository, subcutaneous, subdermal, sublingual, transdermal, and transmucosal. Preferred routes of administration are buccal and buccal. Administration can be local, where the composition is administered directly, close to, locally, near, at, near, or adjacent to the site(s) of disease, e.g., inflammation, or administration can be systemic, where the composition is given to the patient and passes widely through the body, thereby reaching the site(s) of disease. Local administration can be to cells, tissues, organs, and / or organ systems that contain and / or are affected by disease, and / or where signs and / or symptoms of disease are active or prone to occur. Administration can be localized with a local effect, where the composition is applied directly to the location where its action is desired. Administration can be enteral, where the desired effect is systemic (non-local), where the composition is administered via the digestive tract. Administration can be parenteral, where the desired effect is systemic, where the composition is administered by a route other than the digestive tract.
[0064] In some embodiments, the present invention contemplates a composition comprising a therapeutically effective amount of one or more compounds of various embodiments of the present invention.In some embodiments, the composition is useful in a method for treating cancer, the method comprising administering a therapeutically effective amount of one or more compounds of any claim to a patient in need thereof.In some aspects, various embodiments of the present invention contemplate the compounds of formula (I), (II), and (III) used as medicines to treat patients in need of relief from cancer, including but not limited to prostate cancer, lung cancer, breast cancer, or pancreatic cancer.
[0065] In some other embodiments, the present invention contemplates compositions comprising a therapeutically effective amount of a compound of the present invention together with a therapeutically effective amount of one or more other compounds of the same or different mechanism of action to a patient in need of relief from said cancer.
[0066] The term "therapeutically effective amount" as used herein refers to an amount of one or more compounds of various embodiments of the present invention that elicits a biological or medical response in a tissue system, animal, or human that is sought by a researcher, veterinarian, medical doctor, or other clinician, including the alleviation of symptoms of the disease or disorder being treated. In some embodiments, a therapeutically effective amount is one that can treat or alleviate a disease or symptoms of a disease at a reasonable benefit / risk ratio applicable to any medical treatment. However, it should be understood that the total daily usage of the compounds and compositions described herein may be determined by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend on a variety of factors, including the condition and severity of the condition being treated; the activity of the specific compound used; the specific composition used; the age, weight, general health, sex, and diet of the patient: the time of administration, route of administration, and excretion rate of the specific compound used; the duration of treatment; drugs used in combination or simultaneously with the specific compound used; and similar factors well known to a researcher, veterinarian, medical doctor, or other clinician. It is also understood that the therapeutically effective amount can be selected with regard to any toxicity or other undesirable side effects that may arise during administration of one or more of the compounds described herein.
[0067] In some exemplary embodiments, the present disclosure provides a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, wherein, independently, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; C represents three identical or different substituents, each independently being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above three, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0068] In some exemplary embodiments, the present disclosure provides a compound of formula (II): [ka] and for a 20S CP stimulant compound having the formula: A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0069] In some exemplary embodiments, the disclosure relates to a 20S CP stimulant compound having formula (II) as disclosed herein, wherein: A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; B represents five of the same or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl.
[0070] In some exemplary embodiments, the disclosure provides a 20S CP stimulant compound having formula (II) as disclosed herein, [ka] The present invention relates to a compound wherein
[0071] In some exemplary embodiments, the present disclosure provides a compound of formula (III): [ka] and for a 20S CP stimulant compound having the formula: X - is the counter ion, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; D represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0072] In some exemplary embodiments, the present disclosure provides a compound of formula (IV): [ka] and for a 20S CP stimulant compound having the formula: X - is the counter ion, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; Or any two adjacent substituents of the above five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety.
[0073] In some exemplary embodiments, the disclosure relates to a 20S CP stimulator compound having formula (I), (II), (III), or (IV) as disclosed herein, wherein two of the five substituents of A are halo.
[0074] In some exemplary embodiments, the disclosure relates to a 20S CP stimulator compound having formula (I), (II), (III), or (IV) as disclosed herein, wherein two of the five substituents of B are halo.
[0075] In some exemplary embodiments, the present disclosure relates to a 20S CP stimulant compound having formula (I), (II), (III), or (IV) as disclosed herein, wherein the counterion is a halide.
[0076] In some exemplary embodiments, the disclosure provides a 20S CP stimulant compound having formula (I), (II), (III), or (IV) as disclosed herein, [ka] The present invention relates to a compound wherein
[0077] In certain other exemplary embodiments, the present disclosure relates to pharmaceutical compositions comprising a 20S CP stimulant compound having formula (I), (II), (III), or (IV) disclosed herein.
[0078] In certain other exemplary embodiments, the present disclosure relates to a pharmaceutical composition comprising a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein, wherein said compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS).
[0079] In some other exemplary embodiments, the present disclosure relates to a pharmaceutical composition comprising a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein, for use in treating a disease caused by dysregulation of the UPS.
[0080] In some other exemplary embodiments, the disclosure relates to the use of a pharmaceutical composition in the preparation of a medicament for treating a disease caused by dysregulation of the UPS, wherein said pharmaceutical composition comprises a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein.
[0081] In some other exemplary embodiments, the disclosure relates to the use of a pharmaceutical composition in the preparation of a medicament for treating a disease caused by dysregulation of the UPS, wherein said pharmaceutical composition comprises a 20S CP stimulator compound having formula (I), (II), (III), or (IV) disclosed herein, wherein said compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS).
[0082] In some other exemplary embodiments, the present disclosure provides a compound of general formula (I): [ka] or a pharma- ceutical acceptable salt thereof, wherein the compound has the formula: wherein, independently, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; C represents three identical or different substituents, each independently being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above three, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; It concerns the method.
[0083] In some other exemplary embodiments, the present disclosure provides a compound represented by the general formula (II): [ka] 1. A method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having the formula: A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; It concerns the method.
[0084] In some other exemplary embodiments, the disclosure provides a method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having the general formula (II) disclosed herein, wherein: A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; It concerns the method.
[0085] In some other exemplary embodiments, the disclosure provides a method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having a general formula (II): [ka] This relates to a method.
[0086] In some other exemplary embodiments, the present disclosure provides a compound represented by general formula (III): [ka] 1. A method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having the formula: X - is the counter ion, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; D represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of the above five, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; It concerns the method.
[0087] In some other exemplary embodiments, the present disclosure relates to a method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having general formula (I), (II), (III), or (IV), wherein the compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS).
[0088] In some other exemplary embodiments, the disclosure relates to a method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having general formula (I), (II), (III), or (IV), wherein the compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS), and wherein the compound is for use in treating a disease caused by dysregulation of the UPS.
[0089] In some other exemplary embodiments, the disclosure relates to a method for treating a disease in a subject caused by dysregulation of the UPS, comprising administering to the subject a therapeutically effective amount of a compound having general formula (I), (II), (III), or (IV), wherein the compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS), and wherein the compound is for use in the preparation of a medicament for treating a disease caused by dysregulation of the UPS, wherein the compound is an effective stimulator of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS).
[0090] In some embodiments, the 20S CP stimulator compound is a miconazole analog, or a derivative, prodrug, or pharma- ceutically acceptable salt thereof, as shown in FIG. 1 and further exemplified by the compounds in Table 1 below.
[0091] [Table 1-1] [Table 1-2] [Table 1-3]
[0092] Introduction to the Proteasome and Stimulation
[0093] The 20S CP is composed of four heptameric rings that create a barrel-like structure of the α, β, β, α form. 13 Three of the β-subunits (β1, β2, and β5) are responsible for the catalytic activity of the 20S CP. The α-subunits form the gate of the 20S CP, inside which substrates must enter and be degraded. Several small molecule stimulators of the 20S CP have been discovered, most of which appear to affect the gate. 14~18 Studies have shown that 20S CP in solution can be in either the open-gate or closed-gate state, with approximately one-quarter of all 20S CP being in the open-gate state. 19 Small molecules could stabilize this conformation and increase the percentage of the 20S CP in this open-gate state. Another way to stimulate the 20S CP is to directly affect at least one of the catalytic sites, increasing its hydrolytic activity. Only a few stimulators of this type have been discovered. 15、20 The majority of research has focused on small molecules that modulate the gate, also known as "gate openers."
[0094] In this patent, we introduce miconazole, a previously unreported small molecule stimulator of the 20S CP, and describe the synthesis of various derivatives of this small molecule, FIG. 1.
[0095] Miconazole was discovered as a stimulator of the 20S CP during screening of the NIH Clinical Collection (NCC) using our previously described FRET assay. 15、21However, this screen utilized a modulated FRET peptide in which aspartic acid was substituted for phenylalanine. Hydrolysis of the FRET peptide generates a fluorescent signal that can be monitored over time to determine the activity level of 20S CP. Screening of NCC was performed in 384-well plates on a Tecan plate reader, monitoring the emission wavelength of the FRET peptide over a period of 1 hour. Each compound was screened in singlet form at a final concentration of 25 μM. A linear regression was performed on the change in fluorescence over time to generate a slope. This value for each compound was then compared to a DMSO control (20S CP basal level activity), which was included in triplicate on each plate. Primary hit compounds were determined to have a slope 50% greater than the DMSO control.
[0096] Among other compounds, miconazole was the primary hit from this screen, increasing 20S CP activity by 299%. All primary hits were then validated in triplicate using this reporter and a standard FRET reporter. After triple validation, hits were purchased from other sources and once again tested for their respective effects on 20S CP using the standard FRET assay (Figure 2A).
[0097] To determine the general mechanism of action of miconazole (i.e., an allosteric regulator of hydrolytic activity, or "gate opener"), a series of FRET assays were performed with 25 μM miconazole using the immunoproteasome (iCP) and the 26S proteasome. The immunoproteasome contains a high degree of similarity to the canonical 20S CP (sCP); however, the catalytic β-subunit is exchanged, resulting in variability in the hydrolytic activity of this protease compared to the canonical 20S CP. 22 The gates of both the immunoproteasome and the 20S CP are identical: the 26S proteasome is a standard 20S CP capped by a 19S regulatory particle, which binds to the α-ring of the 20S CP and creates an open gate conformation. 23The gate opener of 20S CP should still affect the activity of immunoproteasome; however, since the gate is blocked in 26S proteasome, this type of stimulant is not likely to be effective with this isoform of proteasome.Similarly, a stimulant that can specifically increase at least one of the catalytic sites of 20S CP may not be effective with immunoproteasome, since this isoform contains different catalytic subunits from standard 20S CP.This type of stimulant will still affect the activity of 26S proteasome, since it contains standard 20S CP.
[0098] Miconazole is thought to act as a "gate-opening" small molecule stimulator of the 20S CP. Our studies show that miconazole is an effective stimulator of 20S CP and immunoproteasome activity, while having no effect on the 26S proteasome (Figure 2B).
[0099] Following mechanistic analysis of miconazole, a dose-response study was performed using the FRET assay and standard 20S CP. This study demonstrated that miconazole increased the EC 50 or 20 μM, an effective concentration that elicits 50% of its maximal stimulatory effect (FIG. 2C).
[0100] The effect of a stimuli on peptide hydrolysis is not always interpreted as protein degradation. Therefore, miconazole was used in a biochemical assay using purified proteins to determine its effect on 20S CP-mediated degradation of 15 different proteins, some of which are known substrates of the 20S CP. Miconazole was incubated at 25 μM with 20S CP and 200 ng of purified protein for 2 h in triplicate. Reactions were then quenched with gel loading buffer and samples were run on SDS-PAGE gels and stained with Coommassie. Quantitation of band density was performed for all samples and compared within each gel. Miconazole-treated samples were compared to samples lacking the 20S CP and containing only purified protein as controls and to samples with the 20S CP treated with DMSO. The effect of miconazole on the degradation of these 15 proteins compared to the basal level of degradation is shown in Figure 3.
[0101] Scheme 1. Synthesis of miconazole derivatives. [ka] a) Compound (1) was weighed and dissolved in ACN in a round-bottom flask under Ar atmosphere (mixture 1). In a separate round-bottom flask, Me 3 SI and KOH were dissolved in ACN, also under Ar atmosphere, and stirred for a few minutes (mixture 2). After 2-3 min of reaction, mixture 1 was slowly added to mixture 2 via syringe, and the resulting solution was stirred and heated at 60-65° C. under Ar atmosphere for 3 to 5 h. The reaction was monitored by TLC using EtOAc:HEX as the mobile phase and 2,4-DNP as the visualization technique. After completion, the crude was purified by H 2 The mixture was quenched with O or brine and extracted with HEX in a 1:1 ratio. The combined organics were washed with Na 2 SO 4 The crude material was dried using hexanes and concentrated under reduced pressure and was pure enough for the next step. b) NaH and imidazole were weighed and dissolved in dry DMF in a round bottom flask and the resulting solution was stirred under Ar atmosphere for 30 to 35 minutes (solution 1). In a different round bottom flask, compound (2) was dissolved in dry DMF and then added to solution 1 via syringe. The resulting mixture was stirred under Ar atmosphere at room temperature overnight until the starting material was consumed as revealed by TLC using EtOAc:HEX as the mobile phase. The resulting mixture was quenched using a few mL of brine and extracted with EtOAc. This organic solution was then rinsed several times with H 2 Wash with NaCl and brine. 2 SO 4 The mixture was dried using hexanes and concentrated under reduced pressure, and the resulting crude material was purified by silica column chromatography using a 1% solution of TEA in EtOAc:HEX. c) NaH and compound (3) were weighed and dissolved in dry DMF in a round bottom flask and the resulting solution was stirred under Ar atmosphere for 40-45 min (solution 1). In a different round bottom flask, compound (4) was dissolved in dry DMF and then added to solution 1 via syringe. The resulting mixture was stirred under Ar atmosphere at room temperature for 3-5 h until the starting material was consumed as revealed by TLC using EtOAc:HEX as the mobile phase. The resulting mixture was quenched using a few mL of brine and extracted with EtOAc. This organic solution was then rinsed several times with H 2 Wash with NaCl and brine. 2 SO 4 The mixture was dried using hexanes and concentrated under reduced pressure, and the resulting crude material was purified by silica column chromatography using a 1% solution of TEA in EtOAc:HEX.
[0102] The efficacy of miconazole as a 20S CP stimulator in cellular assays has been demonstrated. In this study, HEK-293T cells are transiently transfected to express a GFP-α-synuclein construct. α-synuclein is a known substrate of the 20S CP, whereas GFP is too large and sufficiently folded to enter the gate of the 20S CP for degradation. Thus, 20S CP-mediated hydrolysis of this construct degrades the α-synuclein portion, leaving free GFP. After transfection, cells were plated on 12-well plates and then treated with DMSO (control) or 25 μM miconazole for 24 hours. After this period, cells were lysed and analyzed by Western blot for GFP. Because 20S CP-mediated hydrolysis of this fusion protein can degrade only the α-synuclein portion, the Western blot produces two distinct bands corresponding to the complete fusion protein (GFP-α-synuclein) and free GFP. Quantitative analysis was performed on each sample to quantify the relative density of each band. The ratio of free GFP to GFP-α-synuclein fusion was calculated. This calculated ratio of miconazole-treated cell lysates was compared to the control (DMSO) to determine the change in 20S CP-mediated degradation. In this assay, miconazole was shown to enhance the degradation of α-synuclein by 200-300% higher than the DMSO control.
[0103] Derivative synthesis and testing.
[0104] Each derivative of miconazole is tested in triplicate at 25μM using our standard FRET assay.Each plate contains 25μM miconazole in triplicate as a positive control.This is also done to determine how well the derivatives compare with the original compound.The derivatives that increase 20S CP activity are then used for further studies.
[0105] We performed: mechanistic analysis (FRET assays using the immunoproteasome and 26S proteasome), EC 50Studies similar to those described above will be performed for each derivative that warrants further evaluation, including dose-response studies to determine the potency of miconazole in cells, and a GFP-α-synuclein cellular assay in which miconazole is included as a positive control.
[0106] Those skilled in the art will appreciate that numerous modifications may be made to the specific implementations described above, and the implementations should not be limited to the specific limitations described. Other implementations may be possible.
[0107] While the present disclosure has been illustrated and described in detail in the drawings and the foregoing description, it is to be understood that it is to be considered as illustrative and not limiting in character, that only certain embodiments have been shown and described, and that all changes and modifications within the spirit of the invention are desired to be protected. The scope of the method and apparatus of the present invention is intended to be defined by the following claims. It should be understood, however, that the present disclosure may be practiced otherwise than as specifically described and illustrated without departing from its spirit or scope. Those skilled in the art should appreciate that various alternatives to the embodiments described herein may be employed in the implementation of the claims without departing from the spirit and scope defined in the following claims. References cited: [ka] [ka] The present invention provides, for example, the following items. (Item 1) Formula (I) [ka] or a pharma- ceutically acceptable salt thereof, wherein, independently, A represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of said five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; B represents five identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of said five, together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; C represents three identical or different substituents, each individually being hydrogen, halo, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; or any two adjacent substituents of said three, taken together with the carbons to which they are attached, form an optionally substituted cyclic or heterocyclic moiety; A compound or a pharma- ceutically acceptable salt thereof. (Item 2) The compound is represented by the formula (II)
change
change
change
change
change
change
change
change
change
change
Claims
1. A compound of the following in the preparation of a medicament for treating a disease caused by dysregulation of the UPS: 【Chemistry 31】 wherein said compounds are effective stimulators of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS), and said one or more compounds are present in said pharmaceutical composition in a therapeutically effective amount for treating a disease caused by dysregulation of said UPS.
2. For treating a disease caused by dysregulation of the UPS, a compound comprising: 【Chemistry 31】 wherein said compounds are effective stimulators of the 20S core particle (CP) of the ubiquitin-proteasome system (UPS), and said one or more compounds are present in said pharmaceutical composition in a therapeutically effective amount for treating a disease caused by dysregulation of said UPS.
Citation Information
Patent Citations
JP1975039664A
JP1975106959A
N-benzylazolium derivative
JP1998114758A
Aralkylbenzyl ether compounds, methods for producing the same, intermediate compounds, uses of such compounds, methods for treatment and / or prevention, pharmaceutical compositions and medicines containing the same
JP2013503111A
Methods of Preventing Toxicity of Platinum Drugs
JP2018521133A
